Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06282159 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

A Phase 2 study of Myasthenia Gravis, Generalized, sponsored by Dianthus Therapeutics.

Active
Registry status
Phase 2
Development phase
65
Enrollment target
20
Study locations

NCT06282159 is a Phase 2 study of Myasthenia Gravis, Generalized that is active but no longer recruiting, run by Dianthus Therapeutics. The registered enrollment target is 65 participants, below the 1,316-participant average among 3 other Myasthenia Gravis, Generalized trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06282159, a Phase 2 study of Myasthenia Gravis, Generalized, is active but no longer recruiting, sponsored by Dianthus Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
65 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Conditions Studied

Myasthenia Gravis, Generalized

Interventions

  • DRUG Placebo
  • DRUG DNTH103

Study Locations (20)

Texas

  • Clinical Study Site - Dallas
  • Clinical Study Site - Dallas
  • Clinical Study Site #2 - Houston
  • Clinical Study Site - Houston
  • Clinical Study Site - Lubbock

Florida

  • Clinical Study Site - Boca Raton
  • Clinical Study Site - Bradenton
  • Clinical Study Site - Maitland
  • Clincal Study Site - Tampa

Ohio

  • Clinical Study Site - Cincinnati
  • Clinical Study Site - Columbus

Arizona

  • Clinical Study Site - Phoenix

California

  • Clinical Study Site - Irvine

Connecticut

  • Clinical Study Site - Stamford

Illinois

  • Clinical Study Site - O'Fallon

Kansas

  • Clinical Study Site - Kansas City

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2024-02-23
Est. Completion 2027-08
Phase Phase 2

Sponsor

Dianthus Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06282159

The ClinicalTrials.gov registry entry for NCT06282159 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,316-participant average among 3 other Myasthenia Gravis, Generalized trials with a reported enrollment target (95% lower). The listed sponsor is Dianthus Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myasthenia Gravis, Generalized appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06282159 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT06282159 about?

NCT06282159 is a clinical study titled "A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)". The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

What is the current status of trial NCT06282159?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2024-02-23. Estimated completion is 2027-08.

What conditions does trial NCT06282159 study?

This clinical trial studies the following conditions: Myasthenia Gravis, Generalized.

What interventions are being tested in trial NCT06282159?

The interventions under investigation include: Placebo (DRUG), DNTH103 (DRUG).

Who is sponsoring clinical trial NCT06282159?

This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06282159 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myasthenia Gravis, Generalized

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myasthenia Gravis, Generalized

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.